Therapeutic effect of vitamin D3-containing nanostructured lipid carriers on inflammatory bowel disease

Khadijah Zai, Masato Hirota, Takahiro Yamada, Narumi Ishihara, Takeshi Mori, Akihiro Kishimura, Koichiro Suzuki, Koji Hase, Yoshiki Katayama

研究成果: ジャーナルへの寄稿記事

3 引用 (Scopus)

抄録

The active form of vitamin D3, 1,25(OH)2D3 has been found to exert multiple effects on the suppression of progression of inflammatory bowel disease (IBD). Vitamin D3 has been gathering attention as a therapy for IBD. However, the clinical trials conducted to date revealed that a relatively high dosage of vitamin D3 was required to see a significant therapeutic effect. Thus, effective formulation and delivery of vitamin D3 to colonic inflammatory lesions will be required. Herein we describe the preparation of a nanostructured lipid carrier (NLC) for the encapsulation of 1,25(OH)2D3 for colonic delivery via oral administration. The optimized fabrication procedure enabled the incorporation of 1,25(OH)2D3 in the NLC by minimizing the destruction of chemically unstable 1,25(OH)2D3. The obtained NLCs orally delivered 1,25(OH)2D3 to the colon in mice and maintained a high concentration of 1,25(OH)2D3 in the colonic tissue for at least 12 h. The NLC showed multiple effects on the suppression of symptoms of colitis induced by dextran sodium sulfate, namely maintaining crypt structure, reducing the tissue concentration of inflammatory cytokines, suppressing the infiltration of polymorphonuclear leukocytes, and augmenting anti-inflammatory CX3CR1high macrophages. Our NLCs containing 1,25(OH)2D3 may be an alternative treatment for IBD therapy.

元の言語英語
ページ(範囲)94-102
ページ数9
ジャーナルJournal of Controlled Release
286
DOI
出版物ステータス出版済み - 9 28 2018

Fingerprint

Cholecalciferol
Therapeutic Uses
Inflammatory Bowel Diseases
Lipids
Dextran Sulfate
Colitis
Oral Administration
Colon
Neutrophils
Anti-Inflammatory Agents
Therapeutics
Macrophages
Clinical Trials
Cytokines

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

これを引用

Therapeutic effect of vitamin D3-containing nanostructured lipid carriers on inflammatory bowel disease. / Zai, Khadijah; Hirota, Masato; Yamada, Takahiro; Ishihara, Narumi; Mori, Takeshi; Kishimura, Akihiro; Suzuki, Koichiro; Hase, Koji; Katayama, Yoshiki.

:: Journal of Controlled Release, 巻 286, 28.09.2018, p. 94-102.

研究成果: ジャーナルへの寄稿記事

Zai, Khadijah ; Hirota, Masato ; Yamada, Takahiro ; Ishihara, Narumi ; Mori, Takeshi ; Kishimura, Akihiro ; Suzuki, Koichiro ; Hase, Koji ; Katayama, Yoshiki. / Therapeutic effect of vitamin D3-containing nanostructured lipid carriers on inflammatory bowel disease. :: Journal of Controlled Release. 2018 ; 巻 286. pp. 94-102.
@article{944f4dab492943d5ae6f5d227ce2f1e3,
title = "Therapeutic effect of vitamin D3-containing nanostructured lipid carriers on inflammatory bowel disease",
abstract = "The active form of vitamin D3, 1,25(OH)2D3 has been found to exert multiple effects on the suppression of progression of inflammatory bowel disease (IBD). Vitamin D3 has been gathering attention as a therapy for IBD. However, the clinical trials conducted to date revealed that a relatively high dosage of vitamin D3 was required to see a significant therapeutic effect. Thus, effective formulation and delivery of vitamin D3 to colonic inflammatory lesions will be required. Herein we describe the preparation of a nanostructured lipid carrier (NLC) for the encapsulation of 1,25(OH)2D3 for colonic delivery via oral administration. The optimized fabrication procedure enabled the incorporation of 1,25(OH)2D3 in the NLC by minimizing the destruction of chemically unstable 1,25(OH)2D3. The obtained NLCs orally delivered 1,25(OH)2D3 to the colon in mice and maintained a high concentration of 1,25(OH)2D3 in the colonic tissue for at least 12 h. The NLC showed multiple effects on the suppression of symptoms of colitis induced by dextran sodium sulfate, namely maintaining crypt structure, reducing the tissue concentration of inflammatory cytokines, suppressing the infiltration of polymorphonuclear leukocytes, and augmenting anti-inflammatory CX3CR1high macrophages. Our NLCs containing 1,25(OH)2D3 may be an alternative treatment for IBD therapy.",
author = "Khadijah Zai and Masato Hirota and Takahiro Yamada and Narumi Ishihara and Takeshi Mori and Akihiro Kishimura and Koichiro Suzuki and Koji Hase and Yoshiki Katayama",
year = "2018",
month = "9",
day = "28",
doi = "10.1016/j.jconrel.2018.07.019",
language = "English",
volume = "286",
pages = "94--102",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

TY - JOUR

T1 - Therapeutic effect of vitamin D3-containing nanostructured lipid carriers on inflammatory bowel disease

AU - Zai, Khadijah

AU - Hirota, Masato

AU - Yamada, Takahiro

AU - Ishihara, Narumi

AU - Mori, Takeshi

AU - Kishimura, Akihiro

AU - Suzuki, Koichiro

AU - Hase, Koji

AU - Katayama, Yoshiki

PY - 2018/9/28

Y1 - 2018/9/28

N2 - The active form of vitamin D3, 1,25(OH)2D3 has been found to exert multiple effects on the suppression of progression of inflammatory bowel disease (IBD). Vitamin D3 has been gathering attention as a therapy for IBD. However, the clinical trials conducted to date revealed that a relatively high dosage of vitamin D3 was required to see a significant therapeutic effect. Thus, effective formulation and delivery of vitamin D3 to colonic inflammatory lesions will be required. Herein we describe the preparation of a nanostructured lipid carrier (NLC) for the encapsulation of 1,25(OH)2D3 for colonic delivery via oral administration. The optimized fabrication procedure enabled the incorporation of 1,25(OH)2D3 in the NLC by minimizing the destruction of chemically unstable 1,25(OH)2D3. The obtained NLCs orally delivered 1,25(OH)2D3 to the colon in mice and maintained a high concentration of 1,25(OH)2D3 in the colonic tissue for at least 12 h. The NLC showed multiple effects on the suppression of symptoms of colitis induced by dextran sodium sulfate, namely maintaining crypt structure, reducing the tissue concentration of inflammatory cytokines, suppressing the infiltration of polymorphonuclear leukocytes, and augmenting anti-inflammatory CX3CR1high macrophages. Our NLCs containing 1,25(OH)2D3 may be an alternative treatment for IBD therapy.

AB - The active form of vitamin D3, 1,25(OH)2D3 has been found to exert multiple effects on the suppression of progression of inflammatory bowel disease (IBD). Vitamin D3 has been gathering attention as a therapy for IBD. However, the clinical trials conducted to date revealed that a relatively high dosage of vitamin D3 was required to see a significant therapeutic effect. Thus, effective formulation and delivery of vitamin D3 to colonic inflammatory lesions will be required. Herein we describe the preparation of a nanostructured lipid carrier (NLC) for the encapsulation of 1,25(OH)2D3 for colonic delivery via oral administration. The optimized fabrication procedure enabled the incorporation of 1,25(OH)2D3 in the NLC by minimizing the destruction of chemically unstable 1,25(OH)2D3. The obtained NLCs orally delivered 1,25(OH)2D3 to the colon in mice and maintained a high concentration of 1,25(OH)2D3 in the colonic tissue for at least 12 h. The NLC showed multiple effects on the suppression of symptoms of colitis induced by dextran sodium sulfate, namely maintaining crypt structure, reducing the tissue concentration of inflammatory cytokines, suppressing the infiltration of polymorphonuclear leukocytes, and augmenting anti-inflammatory CX3CR1high macrophages. Our NLCs containing 1,25(OH)2D3 may be an alternative treatment for IBD therapy.

UR - http://www.scopus.com/inward/record.url?scp=85050176611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050176611&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2018.07.019

DO - 10.1016/j.jconrel.2018.07.019

M3 - Article

AN - SCOPUS:85050176611

VL - 286

SP - 94

EP - 102

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -